DE69611247D1 - Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung - Google Patents

Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung

Info

Publication number
DE69611247D1
DE69611247D1 DE69611247T DE69611247T DE69611247D1 DE 69611247 D1 DE69611247 D1 DE 69611247D1 DE 69611247 T DE69611247 T DE 69611247T DE 69611247 T DE69611247 T DE 69611247T DE 69611247 D1 DE69611247 D1 DE 69611247D1
Authority
DE
Germany
Prior art keywords
drug
delivery systems
drug delivery
supplied
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69611247T
Other languages
English (en)
Other versions
DE69611247T2 (de
Inventor
C Farinas
M Miller
L Soni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE69611247D1 publication Critical patent/DE69611247D1/de
Publication of DE69611247T2 publication Critical patent/DE69611247T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
DE69611247T 1995-09-08 1996-09-06 Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung Expired - Lifetime DE69611247T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52586795A 1995-09-08 1995-09-08
US08/708,389 US5906830A (en) 1995-09-08 1996-09-04 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
PCT/US1996/014331 WO1997010812A2 (en) 1995-09-08 1996-09-06 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Publications (2)

Publication Number Publication Date
DE69611247D1 true DE69611247D1 (de) 2001-01-18
DE69611247T2 DE69611247T2 (de) 2001-09-06

Family

ID=27061927

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69611247T Expired - Lifetime DE69611247T2 (de) 1995-09-08 1996-09-06 Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung

Country Status (12)

Country Link
US (1) US5906830A (de)
EP (1) EP0848608B1 (de)
JP (1) JP3566301B2 (de)
AT (1) ATE198042T1 (de)
AU (1) AU6968296A (de)
CA (1) CA2229184C (de)
DE (1) DE69611247T2 (de)
DK (1) DK0848608T3 (de)
ES (1) ES2154832T3 (de)
GR (1) GR3035441T3 (de)
PT (1) PT848608E (de)
WO (1) WO1997010812A2 (de)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245347B1 (en) * 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US6284266B1 (en) 1995-07-28 2001-09-04 Zars, Inc. Methods and apparatus for improved administration of fentanyl and sufentanil
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
BR9710128A (pt) * 1996-07-03 1999-08-10 Alza Corpora Dispositivo para fornecimento de medicamento e processo de fabricação
TW358031B (en) * 1997-04-11 1999-05-11 Akze Nobel N V Drug delivery system for 2 or more active substances
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US7066884B2 (en) * 1998-01-08 2006-06-27 Sontra Medical, Inc. System, method, and device for non-invasive body fluid sampling and analysis
US8287483B2 (en) 1998-01-08 2012-10-16 Echo Therapeutics, Inc. Method and apparatus for enhancement of transdermal transport
US20060015058A1 (en) * 1998-01-08 2006-01-19 Kellogg Scott C Agents and methods for enhancement of transdermal transport
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US6726673B1 (en) 1999-05-24 2004-04-27 Zars, Inc. Methods and apparatus for improved administration of testosterone pharmaceuticals
US6955819B2 (en) 1998-09-29 2005-10-18 Zars, Inc. Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances
US20040171980A1 (en) 1998-12-18 2004-09-02 Sontra Medical, Inc. Method and apparatus for enhancement of transdermal transport
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ATE322889T1 (de) 1999-02-08 2006-04-15 Alza Corp Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6280763B1 (en) 1999-05-10 2001-08-28 Pierce Management, Llc Apparatus and method for transdermal delivery of bupropion
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
CN1195505C (zh) 1999-07-02 2005-04-06 Lts勒曼治疗系统股份公司 以聚硅氧烷及亲两性溶剂为基础的微贮存系统
US6453648B1 (en) 1999-07-06 2002-09-24 Zars, Inc. Method for manufacturing a heat generating apparatus
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
DE10012908B4 (de) * 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
DE10103860B4 (de) * 2001-01-30 2004-12-23 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Verabreichung carboxylgruppenhaltiger, nichtsteroidaler Antiphlogistika, sowie Verfahren zu seiner Herstellung
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
KR20050059072A (ko) * 2002-08-30 2005-06-17 알자 코포레이션 엠보싱 및 기록가능한 다층 지지 구조물
US20040086551A1 (en) 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
PT1426049E (pt) * 2002-12-02 2005-09-30 Sanol Arznei Schwarz Gmbh Administracao iontoforetica de rotigotina para o tratamento da doenca de parkinson
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
BRPI0407615B8 (pt) 2003-02-21 2021-05-25 Bayer Ip Gmbh sistema terapêutico transdérmico estável à radiação ultravioleta
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
WO2005025549A2 (en) * 2003-09-10 2005-03-24 Noven Pharmaceuticals, Inc. Multi-layer transdermal drug delivery device
GB0322342D0 (en) * 2003-09-23 2003-10-22 Gamble Reed Skin patch
CN100457064C (zh) * 2003-10-28 2009-02-04 诺芬药品公司 透皮递药装置
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
WO2006041907A2 (en) * 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Transdermal delivery of estradiol
ATE471146T1 (de) * 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
US8252320B2 (en) * 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US20060094944A1 (en) * 2004-10-28 2006-05-04 Sontra Medical Corporation System and method for analyte sampling and analysis with error correction
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20060188558A1 (en) * 2005-02-18 2006-08-24 Mylan Technologies, Inc. Transdermal systems having control delivery system
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1888001B1 (de) * 2005-06-10 2014-08-06 Syneron Medical Ltd. Patch zur transdermalen wirkstofffreisetzung
US8287923B2 (en) * 2005-06-10 2012-10-16 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating immune disorders
TWI419717B (zh) * 2005-06-17 2013-12-21 Altea Therapeutics Corp 滲透傳送系統及其使用方法
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
NO346660B1 (no) 2005-10-12 2022-11-21 Unimed Pharmaceuticals Llc Forbedret testosterongel og fremgangsmåte til anvendelse
US7432069B2 (en) * 2005-12-05 2008-10-07 Sontra Medical Corporation Biocompatible chemically crosslinked hydrogels for glucose sensing
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス,インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
WO2007147052A2 (en) 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
US8812071B2 (en) * 2007-03-07 2014-08-19 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
JP2010525881A (ja) 2007-04-27 2010-07-29 エコー セラピューティクス, インコーポレイテッド 被検体の検知または経皮的薬物送達のための皮膚透過装置
CA2704164A1 (en) * 2007-10-29 2009-05-07 Transpharma Medical Ltd. Vertical patch drying
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
US20090269403A1 (en) * 2008-04-24 2009-10-29 Shaked Ze Ev Oral contraceptive dosage forms and methods of making such dosage forms
US20090291127A1 (en) * 2008-05-21 2009-11-26 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
KR101590209B1 (ko) * 2008-05-30 2016-02-01 밀란 인크. 안정화 경피 약물 전달 시스템
US8231906B2 (en) 2008-07-10 2012-07-31 Noven Pharmaceuticals, Inc. Transdermal estrogen device and delivery
CN102164601A (zh) * 2008-09-30 2011-08-24 帝国制药美国公司 经皮延长给药多奈哌齐组合物及其使用方法
WO2010042152A2 (en) * 2008-10-06 2010-04-15 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
CA2757302A1 (en) * 2009-04-01 2010-10-07 Andrew Crockett Methods for treating myofascial, muscle, and/or back pain
CN102427792A (zh) * 2009-05-04 2012-04-25 扎斯制药公司 治疗与神经瘤、神经卡压及其他病况相关联的疼痛的方法
US9186334B2 (en) 2009-05-04 2015-11-17 Nuvo Research Inc. Heat assisted lidocaine and tetracaine for transdermal analgesia
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
RU2648827C2 (ru) * 2010-03-28 2018-03-28 Эвестра, Инк. Внутривлагалищное устройство для доставки лекарственного средства
JP5766475B2 (ja) 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
AU2011237592B2 (en) 2010-04-08 2016-10-27 Emory University Substituted androst-4-ene diones
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012129237A2 (en) 2011-03-20 2012-09-27 Trustees Of Boston University Therapeutic agent for emphysema and copd
EP2704726B1 (de) 2011-05-04 2018-10-31 Trustees of Boston University Protonenantriebskraftstimulation zur potenzierung von aminoglycosid-antibiotika gegen persistente bakterien
JPWO2012165254A1 (ja) 2011-05-31 2015-02-23 久光製薬株式会社 ロピニロール含有貼付剤及びその包装体
US9155710B2 (en) 2011-05-31 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and package thereof
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
EP2543370A1 (de) 2011-07-06 2013-01-09 Georgia Health Sciences University Research Institute, Inc. Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
CA2790749A1 (en) 2011-09-29 2013-03-29 Nitto Denko Corporation Manufacturing method of patch preparation
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
EP3936133A1 (de) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natürliche kombinationshormonersatzformulierungen und therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
JP5270035B1 (ja) * 2012-12-06 2013-08-21 久光製薬株式会社 貼付剤及びその製造方法
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP5307931B1 (ja) 2012-12-27 2013-10-02 久光製薬株式会社 貼付剤及びその製造方法
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
CN103933018A (zh) * 2013-01-18 2014-07-23 江苏康倍得药业有限公司 一种透皮给药系统
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10493027B2 (en) * 2014-08-07 2019-12-03 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi- chambered delivery system for mucosal delivery
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
EP3303286B1 (de) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center An rela von nf-kb anbindende verbindungen zur verwendung bei der behandlung von krebs
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR112018001441A2 (pt) 2015-07-28 2018-09-11 Vyome Biosciences Pvt Ltd antibacterianos terapêuticos e profiláticos
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE217989C (de) *
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US4883669A (en) * 1985-02-25 1989-11-28 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration
JPH066534B2 (ja) * 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
CA2060113A1 (en) * 1991-02-01 1992-08-02 Agis Kydonieus Temperature activated controlled release device
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
DE4237453C1 (de) * 1992-11-06 1993-08-19 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
AU7238896A (en) * 1995-09-14 1997-04-01 Cygnus, Inc. High capacity, superabsorbent drug reservoirs for use in transdermal drug delivery systems
WO1997024148A1 (en) * 1995-12-29 1997-07-10 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents

Also Published As

Publication number Publication date
JP2002504070A (ja) 2002-02-05
DK0848608T3 (da) 2001-02-19
GR3035441T3 (en) 2001-05-31
CA2229184C (en) 2001-07-24
ATE198042T1 (de) 2000-12-15
ES2154832T3 (es) 2001-04-16
EP0848608B1 (de) 2000-12-13
AU6968296A (en) 1997-04-09
PT848608E (pt) 2001-03-30
US5906830A (en) 1999-05-25
JP3566301B2 (ja) 2004-09-15
CA2229184A1 (en) 1997-03-27
EP0848608A2 (de) 1998-06-24
WO1997010812A2 (en) 1997-03-27
DE69611247T2 (de) 2001-09-06

Similar Documents

Publication Publication Date Title
DE69611247T2 (de) Übersättigte transdermale arzneistoffabgabesysteme und verfahren zu deren herstellung
DE68923805D1 (de) Verfahren zur herstellung von optisch aktivem 1,3-butanediol.
DE69330181T2 (de) Mehrschichtiger vliesstoff, verfahren und vorrichtung zu dessen herstellung, sowie diesen vliesstoff enthaltende absorbierende produkte
DE69525444T2 (de) Verfahren zur herstellung von biologisch aktiven siliziumverbindungen in konzentrierter form
DE3673073D1 (de) Therapeutische brausemischung sowie verfahren zu deren herstellung.
DE69402051D1 (de) Wärmetauschelement, verfahren und vorrichtung zu dessen herstellung
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DE3669328D1 (de) Verfahren und anlage zur serienmaessigen, verzugsarmen thermomechanischen behandlung von werkstuecken sowie anwendung des verfahrens.
DE69311320T2 (de) Herstellung von optisch aktiven hydrazinen und aminen
DE60021354D1 (de) Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
DE58901324D1 (de) Verfahren zur herstellung von solarsilicium.
DE68914638T2 (de) Polyaluminosilikat-mikrogel, verfahren und zusammensetzung.
DE3766708D1 (de) Silylgruppen enthaltendes verzweigtes polymerisat, verfahren zu seiner herstellung, ueberzugsmittel auf basis des polymerisats sowie deren verwendung.
DE69204118D1 (de) Flüssigkristallzusammensetzung, Flüssigkristallelement sowie Verfahren zu seiner Herstellung.
DE3579673D1 (de) Polyazaheterozyklische abkoemmlinge, verfahren zu deren herstellung sowie arzneimittelzusammensetzung.
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
DK1006200T3 (da) Fremgangsmåde til fremstilling af udvalgte interstreng-tværbindinger i nukleinsyrer og anvendelser deraf
DK0546389T3 (da) Piperidylmethylsubstituerede chromanderivater som virksomme stoffer til behandling af sygdomme i centralnervesystemet
PL310950A1 (en) Novel imidazole quinoxalinones, method of obtaining them and their application
EP0702960A4 (de) Flüssige globulinzubereitung für die intravenöse injektion, verfahren für ihre herstellung, und methode zur blockierung der globulindimerisierung in besagter zubereitung
NO870869D0 (no) Innretning for forstyrrelse av navigasjonsanlegg basert paa forplanting av lydboelger i vann.
DE69418661T2 (de) Blockcopolymerzusammensetzung, diese enthaltende Heissschmelzkleberzusammensetzung und Verfahren zu deren Herstellung
PT909167E (pt) Dispositivos de fornecimento de drogas e processo de fabrico
DE3787336D1 (de) Verfahren zur Herstellung von Copolyesters, die Anisotropie in geschmolzenem Zustand zeigen.
ATA210477A (de) Verfahren zur herabsetzung der natriumkonzen- tration in aluminiumschmelzen sowie vorrichtung und granulat zur durchfuehrung des verfahrens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN